While medicine is only peripheral to my education, I’ve always found it to be a fascinating subject. The ways in which drug trials are conducted can be quite interesting. And of course there’s the simple issue of how people create something which will vastly improve the quality of life for people currently suffering from various ailments. That said, part of what makes it so interesting is the sheer complexity of medical research. But until recently I hadn’t considered that the funding for that research was probably just as complex.
They were involved in a legal dispute with Relmada Therapeutics. But even on the surface the case seemed very complex. With Laidlaw receiving a temporary restraining order and associated injunction due to concern that they might be spreading misleading information. What makes the case so interesting to me on a personal level is how the funding from Laidlaw ties into the medical advances of Relmada. I was quite aware that medical research was costly. But for some reason it just never occurred to me that the financing which went on for that research might be just as interesting a topic.
I decided to check out Laidlaw’s website to learn more about them. In turn, I actually learned more than I’d expected about two of the executives within the company. Matthew Eitner and James Ahern both had quite a bit of information about themselves on the site. And this really ended up being one of the deciding factors for me. I saw a lot of my own feelings about medicine reflected in their lists of charitable and business ventures. The work with Relmada was hardly a fluke.
Both men had apparently been working hard to ensure that companies could produce new medicines and provide the medical assistance that the world is so in need of. This makes me feel that the company is probably working under an honorable intent.